Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Pancreas - 1 Jan 2013

Yip-Schneider Michele T, Wu Huangbing, Hruban Ralph H, Lowy Andrew M, Crooks Peter A, Schmidt Christian Max

Abstract excerpt

OBJECTIVES: Pancreatic cancer remains one of the deadliest diseases, with limited surgical and treatment options. Two targets of interest include the transcription factor nuclear factor-κB and cyclooxygenase-2, which are constitutively activated and overexpressed, respectively, in human pancreati...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma in Situ

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 2

Share to Cyclooxygenase 2 Inhibitors

Share to Genes, p53

Share to NF-kappa B

Share to Pancreatic Neoplasms

Share to Sesquiterpenes

Source

Identifiers

PMID: 22699205
DOI: 10.1097/MPA.0b013e318254f455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22699205-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.PMID 22699205Read ↗

Mouse models of pancreatic cancerSemantic proximity Read ↗

Genetically engineered mouse models of pancreatic adenocarcinomaSemantic proximity Read ↗

Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.Semantic proximity Read ↗

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncologySemantic proximity Read ↗

Critical role of oncogenic KRAS in pancreatic cancer (Review).Semantic proximity Read ↗

Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.Semantic proximity Read ↗

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.Semantic proximity Read ↗

Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic CancerSemantic proximity Read ↗

Modeling Pancreatic Cancer In VivoSemantic proximity Read ↗

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read ↗

Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol.Semantic proximity Read ↗

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.